3 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 3 of 3 clinical reviews.
Evidence-based review of MOTS-c mitochondrial peptide efficacy differences in Black and African ancestry populations, including pharmacogenomic factors, dosing considerations, and clinical gaps.
A clinician-focused review of MOTS-c dosing considerations for Hispanic and Latino patients, covering mitochondrial genetics, insulin-resistance phenotypes, and what remains unproven.
A clinical review of MOTS-c mitochondrial peptide safety, pharmacogenomics, and dosing considerations specific to Hispanic and Latino patients, including mitochondrial haplogroup data, insulin-resistance phenotypes, and emerging ethnicity-stratified evidence.